Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corp's positive outlook is bolstered by the anticipated increase in revenue from its iDose product, with estimates for FY26 and beyond reflecting a growth of 3.5% to 5.9% due to a rising number of repeat administration patients. Furthermore, the company's domestic non-iDose glaucoma revenue growth is reported to be in the mid-single digits, aligning with broader market trends and demonstrating strength particularly in international markets. The upcoming product launches and expansive pipeline are expected to significantly broaden Glaukos's total addressable market (TAM), supporting revenue growth and enhancing the potential for profitability in the coming years.

Bears say

Glaukos Corp faces significant challenges that contribute to a negative outlook on its stock, including a slowdown in the expected growth of the minimally invasive glaucoma surgery (MIGS) market and slower adoption rates for its key products, such as iDose TR and iStent Infinite. Additionally, there are risks associated with increased competition in the MIGS sector, potential changes in reimbursement policies that could hinder sales, and the possibility of new product launches underperforming or failing to meet anticipated clinical milestones. These factors, combined with poor sales execution and the stagnation of the iDose account pipeline, create a precarious financial environment for the company moving forward.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.